Research programme: anti-archaea therapeutics - Synthetic Biomics

Drug Profile

Research programme: anti-archaea therapeutics - Synthetic Biomics

Alternative Names: Anti-infectives - Synthetic Biomics

Latest Information Update: 07 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cedars-Sinai Health System
  • Developer Cedars-Sinai Health System; Synthetic Biomics
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 07 Oct 2015 No development reported for Obesity in USA (PO)
  • 07 Oct 2015 No development reported for Type-2 diabetes mellitus in USA (PO)
  • 17 Dec 2013 Synthetic Biomics enters into worldwide license and option agreement with Cedars-Sinai to develop new anti-archaea therapies for chronic diseases (e.g. irritable bowel syndrome, obesity and type 2 diabetes)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top